AiCuris-Team mit dem Deutschen Zukunftspreis 2018 ausgezeichnet
AiCuris-Team receives German Future Prize 2018
Schutz bei fehlendem
|12. September 2018
Deutschen Zukunftspreis 2018"
|Video / Podcast
erschließt neue Perspektiven
in der Transplantationsmedizin
AiCuris (from 'Anti-infective Cures') is a pharmaceutical company focused exclusively on the discovery, research and development of novel antiviral and antibacterial agents for the treatment of severe and potentially life-threatening infectious diseases.
Founded in 2006 from Bayer's virology and bacteriology research divisions, AiCuris today has an innovative pipeline of novel anti-infectives and a team of internationally regarded scientists and drug developers. With its tight focus on specialist markets with high medical need, the company is perfectly positioned for growth and success.
Cooperation with Cyclenium
AiCuris to cooperate with Cyclenium Pharma to Develop Novel Anti-Infectives
AiCuris and Cyclenium announced today the signing of a collaboration agreement focused on finding new pharmaceutical compounds for the treatment and prevention of bacterial and viral diseases.
AIC649 Positive Phase 1 Hepatitis B
AiCuris Reports Positive Phase 1 Clinical Trial Results with Immunomodulator AIC649 in Patients with Chronic Hepatitis B